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Okayama University research: Anticancer virus solution provides an alternative to surgery 
(Okayama, 25 February) Researchers at Okayama demonstrate that injection of a virus 
solution followed by tumour removal can eradicate cancer metastasis in lymph nodes 
without the need for preventative surgery. 
 
While early-stage gastrointestinal cancers can be treated non-surgically, once the cancer has 
invaded to a particular depth preventative – ‘prophylactic’ – surgery is routine. The 
frequency of lymph node metastasis increases significantly once the cancer has penetrated 
the submucosal layers, and as there is no way of determining whether the cancer has 
metastasized in the lymph nodes they will be surgically removed just in case. Now 
researchers at Okayama University and the University of California in San Diego have 
demonstrated that injection of a viral solution can eradicate lymph node metastasis making 
prophylactic surgery unnecessary. 
 
To treat early stage cancers a saline solution is injected creating a fluid cushion, which raises 
and isolates the tumour. The tumour is then readily removed by equipment through a 
standard endoscopic viewing tube inserted in the gastrointestinal tract. However if the 
cancer has already penetrated the submucosal layer it will be prone to relapse in the 
lymphatic system.  
 
Toshiyoshi Fujiwara and his colleagues adapted the standard endoscopic treatment by 
injecting a solution of Telomelysin - a virus known to kill epithelial and mesenchymal 
malignant cells - instead of saline solution.  They tested the treatment in a mouse model, 
injecting green-fluorescent-protein-labelled cancer cells into the submucosal layers of the 
rectum, which developed lymph node metastasis. Fluorescence imaging showed that cancer 
cells were successfully eliminated by the treatment  with  virus solution, in contrast to mice 
treated with saline solution instead. In addition, treated mice showed no relapse four weeks 
after the treatment  
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In their report of the results the researchers conclude, “From a clinical view point, this new, 
simple, and robust strategy is a more realistic and promising bench-to-bedside translation 
than prophylactic surgery for ablation of potential lymph node metastases in early 
gastrointestinal cancer patients.” 
 
Background 
Submucosal layer cancer invasion 
Early stage gastrointestinal cancers are defined by the level of the cancer invasion reaching 
no further than the submucosa. Endoscopic treatment removes these tumours by dissecting 
the submucosal layers. 
 
For esophageal gastric and colorectal submucosally invaded cancers the frequency at which 
the cancer is found to metastasize in the lymph nodes is approximately 10 to 20%. The 
lymphatic system distributes fluids, proteins, chemicals, cells and drugs. This makes it a 
major pathway for the spread of metastatic cancers so that cancerous invasion of the 
lymphatic system is particularly problematic.  
 
It is very difficult to determine whether the cancer has metastases in the lymph nodes. As a 
result lymph node surgery just in case is routine when treating esophageal gastric and 
colorectal submucosal cancers, even though in many cases it may not have been necessary. 
 
Anticancer viruses 
Previous research has demonstrated that certain viruses replicate in cancer cells and break 
them down, and may be developed for cancer treatments. The researchers further exploited 
the role of the lymph system in mediating proteins and fluids, a function which makes it 
more prone to exposure to a virus injected in the surrounding area. 
 
The researchers experimented with Telomelysin – a telomerase-dependent, 
tumor-killing replicating adenoviral agent (OBP-301). The virus is known to kill epithelial and 
mesenchymal malignant cells.   
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Exploiting lymphatic functions with the virus 
The researchers first tested the virus on green-fluorescent-protein-labelled colorectal 
cancer cell lines with. Using fluorescence imaging they observed rapid cell death in response 
to injection with the virus while there was no such response in cell lines treated with mutant 
strains of the virus that had replication deficiencies. 
 
The researchers demonstrated how their treatment exploited the lymph node function 
using mouse models injected with red-fluorescent-protein-labelled lymph node 
metastasized cancer cells. After six days the virus labelled with green fluorescent protein 
was injected and fluorescence images showed the position of the virus coincided with the 
metastatic foci in the lymph nodes. 
 
Reference  
Kikuchi S, Kishimoto H, Tazawa H, Hashimoto Y, Kuroda S, Nishizaki M, Nagasaka T, 
Shirakawa Y, Kagawa S, Urata Y, Hoffman RM, Fujiwara T: Biological Ablation of Sentinel 
Lymph Node Metastasis in Submucosally Invaded Early Gastrointestinal Cancer. Mol Ther. 
2014 Dec 19. 
 
DOI: 10.1038/mt.2014.244. 
 
OKAYAMA University  
1-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530 Japan                                   © OKAYAMA University 
 
OU-MRU   Vol.7 Feb 2015 
 
Figure caption  
Cytopathic effect of the virus (OBP-301) on human colorectal cancer cell lines. (a) Green-
fluorescent-protein (GFP)-labelled colorectal cancer cells were infected with replication-
deficient adenovirus (dl312) or the treatment virus (OBP-301) at a multiplicity of injection 
(MOI) of 10. Cell morphology and GFP expression were evaluated at the indicated time 
points by phase-contrast (top panels) and fluorescence (bottom panels) microscopy, 
respectively. Magnification: ×200. Scale bar, 200 μm.  
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About Okayama University 
Okayama University is one of the largest 
comprehensive universities in Japan with 
roots going back to the Medical Training  
Place sponsored by the Lord of Okayama  
and established in 1870. Now with 1,300 
faculty and 14,000 students, the University 
offers courses in specialties ranging from 
medicine and pharmacy to humanities  
a n d  p h y s i c a l  s c i e n c e s .  O k a y a m a  
University is located in the heart of Japan 
approximately 3 hours west of Tokyo by  
Shinkansen. 
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